VACIS

VACIS has developed a platform technology to provide autologous soft tissue solutions to patients. VACIS is trading under the tradename Curotis - www.curotis.nl / https://www.linkedin.com/company/curotis/ The goal of VACIS' products is to improve patients lives by offering autologous tissue alternatives to currently available artificial solutions. The clinical applications range from vascular access to urology. Interest has also been shown in the field of reconstructive surgery and neurology. After extensive preclinical research, with its results published in multiple scientific journals VACIS has successfully concluded their clinical study and is on the pathway to CE certification within the EU. VACIS is providing solutions of the highest quality which is continously monitored through our ISO13485 certification since 2020.